Protalix Seeks Gaucher Drug Approval

Xconomy Boston — 

Protalix Biotherapeutics, the Israel-based developer of a treatment for Gaucher’s disease that aims to compete with Cambridge, MA-based Genzyme, said today it has filed an application for FDA approval of its drug candidate. Protalix is seeking clearance to sell taliglucerase alfa. The company, which earlier this month formed a partnership with Pfizer to co-market the new Gaucher’s product, is seeking to fill the void created by supply shortages of Genzyme’s imiglucerase (Cerezyme), after a viral contamination struck its Allston Landing factory in June.

By posting a comment, you agree to our terms and conditions.

Comments are closed.